StocksMarket.in

Tag "therapies"

 Breaking News

Cipla posts 24% YoY net profit growth in Q1FY22 led by core therapies, COVID portfolio

India business that includes branded formulations, trade generics and consumer health grew by 68% YoY to Rs 2,710 crore driven by volume growth in core therapies and support from existing

Read Full Article

Prospects for US business and leadership in respiratory therapies make Cipla attractive

App Financial Freedom Offer: Subscribe to Moneycontrol Pro and grab benefits worth ?15,000/- 1 Last Updated : Aug 10, 2020 08:15 AM IST | Source: Moneycontrol.com Cipla’s US revenues clocked

Read Full Article

Archives